Local Projects | Agency Profile, Contacts, AOR, Client Relationships

• Per execs in a recent earnings call, the company's consumer health only accounted for 16% of Q3 revenue, though in the US, sales rose 21.1%.
• By the end of 2025, J&J's goal is for pharmaceuticals to individually be a $60b business.
• Post-Covid growth has primarily come from areas such as diagnostic procedures and colonoscopies as well as surgical procedures.
  • J&J's key MedTech players during Q3 included the general surgery sector's wound closure products, the vision sector's contact lenses, and the orthopedics sector's trauma products.
  • Note: While the company will, of course, focus on these products, J&J's consumer business is also still advertising its medicine brands to customers.
• As I briefly mentioned, J&J is in the process of separating from its consumer-oriented business.
  • The process will probably take 18-24 months.
  • The standalone firm will be called Kenvue.
• The company will likely:
  • Continue increasing digital spend for its consumer business (more below) until the two split
  • Ramp up spend for its B2B business under a new DM (more below)
  • Seek new agency partners to support upcoming pharmaceutical- and MedTech-related initiatives
• Target demographic:
  • J&J is primarily targeting medical organizations such as hospitals and doctors' offices.
  • However, since it hasn't yet split off from its consumer goods segment, the company is also still targeting potential and existing customers.
    • When it comes to consumers, J&J is primarily targeting Gen-Z and millennials via digital/paid social advertising.

​​​​​​Recent leadership shifts: